{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PRT064445",
    "query": {
      "intervention": "PRT064445"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PRT064445&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T22:22:07.211Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05548777",
      "title": "Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Anticoagulant-related Major Bleed"
      ],
      "interventions": [
        {
          "name": "Andexanet alfa",
          "type": "DRUG"
        },
        {
          "name": "4F-PCC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 5480,
      "start_date": "2022-09-15",
      "completion_date": "2022-12-20",
      "has_results": false,
      "last_update_posted_date": "2023-11-28",
      "last_synced_at": "2026-09-02T22:22:07.211Z",
      "location_count": 1,
      "location_summary": "Agoura Hills, California",
      "locations": [
        {
          "city": "Agoura Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05548777"
    },
    {
      "nct_id": "NCT03330457",
      "title": "A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Andexanet alfa (bolus)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Betrixaban 80 mg PO QD",
          "type": "DRUG"
        },
        {
          "name": "Andexanet alfa (infusion IV)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Portola Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 18,
      "start_date": "2015-08-06",
      "completion_date": "2016-02-22",
      "has_results": true,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-09-02T22:22:07.211Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03330457"
    },
    {
      "nct_id": "NCT03310021",
      "title": "A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Andexanet alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Portola Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 108,
      "start_date": "2017-08-28",
      "completion_date": "2019-08-13",
      "has_results": true,
      "last_update_posted_date": "2023-02-24",
      "last_synced_at": "2026-09-02T22:22:07.211Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03310021"
    },
    {
      "nct_id": "NCT02207725",
      "title": "A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Andexanet",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Portola Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 68,
      "start_date": "2014-03",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-09-02T22:22:07.211Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02207725"
    },
    {
      "nct_id": "NCT01758432",
      "title": "Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "PRT064445/Apixaban",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo/Apixaban",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Portola Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 54,
      "start_date": "2012-12",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2023-08-07",
      "last_synced_at": "2026-09-02T22:22:07.211Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01758432"
    },
    {
      "nct_id": "NCT04233073",
      "title": "Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Surgery"
      ],
      "interventions": [
        {
          "name": "andexanet alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-06-27",
      "completion_date": "2022-01-25",
      "has_results": true,
      "last_update_posted_date": "2023-03-22",
      "last_synced_at": "2026-09-02T22:22:07.211Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Moreno Valley",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04233073"
    },
    {
      "nct_id": "NCT02220725",
      "title": "A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Andexanet",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Portola Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 80,
      "start_date": "2014-05",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2023-02-10",
      "last_synced_at": "2026-09-02T22:22:07.211Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02220725"
    },
    {
      "nct_id": "NCT02329327",
      "title": "A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Andexanet",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 479,
      "start_date": "2015-04-10",
      "completion_date": "2020-09-24",
      "has_results": true,
      "last_update_posted_date": "2022-02-16",
      "last_synced_at": "2026-09-02T22:22:07.211Z",
      "location_count": 23,
      "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 20 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02329327"
    },
    {
      "nct_id": "NCT03661528",
      "title": "Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Intracranial Hemorrhage"
      ],
      "interventions": [
        {
          "name": "andexanet alfa",
          "type": "DRUG"
        },
        {
          "name": "Usual Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 530,
      "start_date": "2019-06-06",
      "completion_date": "2023-08-09",
      "has_results": true,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-09-02T22:22:07.211Z",
      "location_count": 11,
      "location_summary": "Fort Lauderdale, Florida • Augusta, Georgia • Royal Oak, Michigan + 7 more",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Troy",
          "state": "Michigan"
        },
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03661528"
    },
    {
      "nct_id": "NCT03083704",
      "title": "A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Andexanet alfa (Gen 1 Process 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Apixaban 5 MG",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban 20 MG",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin sodium",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban 60 MG",
          "type": "DRUG"
        },
        {
          "name": "Andexanet alfa (Gen 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Andexanet alfa (Gen 1 Process 3)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Apixaban 10 MG",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban 10 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Portola Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 153,
      "start_date": "2017-02-26",
      "completion_date": "2017-09-28",
      "has_results": false,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-09-02T22:22:07.211Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03083704"
    }
  ]
}